Pharmaceutical industry is a multi-disciplinary, advanced technology and high-tech industry means a high degree of integration of groups involved in public health, social stability and economic development. China's pharmaceutical industry showed rapid upward trend in recent years, by 2010, China has become the world's most promising emerging third-largest pharmaceutical market. The United States, Japan and other developed countries, the development of pharmaceutical industry experience shows that: integrated development of industrial clusters, can maximize the use of regional resources to promote innovation and enhance sustainable development capacity. Northeast of China-focused medicine, antibiotics, industrial base, with the implementation of the pharmaceutical industry cluster-based integrated development of the industry and location advantages.
At present, Heilongjiang Province, Harbin is striving to build the center, Qiqihar, Daqing for the wings, and medium-sized cities and regional centers as an important support resource-based cities of the six industry groups and six industrial base. Harbin Pharmaceutical industry is focused on cultivating one of the five pillar industries, accounted for the balance of the total assets of the Heilongjiang province and the pharmaceutical industry for 70% -80%. Harbin Harbin Pharmaceutical Group has been formed as a leader, Harbin Development Zone pharmaceutical raw materials medicine park and ride out the park as the flank, the pharmaceutical industry, striving to develop the pattern.
Jilin Province, the regional distribution of pharmaceutical industry is relatively concentrated, has been formed to Tonghua City, Changchun City and Yanbian (Dunhua City) as the center of the cluster. In 2005, Changchun City, approved by the National Development and Reform Commission for the first national biological industrial base, Changchun City and Tonghua City was approved by the Ministry of Commerce as a "national medicine export base." December 2006 and December 2007 respectively, the Ministry of Commerce, Science and Technology has awarded the city of Tonghua and Changchun City, State "science and technology innovation base (biomedical category)." This is for the construction of pharmaceutical industrial clusters in Jilin Province has laid a solid foundation.
Liaoning Province to consolidate and develop the advantages of the production of chemical raw materials and preparations based on traditional Chinese medicine industry is to develop and speed up the digitization of modern biotechnology and medical device industry process. Among them, the development of Shenyang chemical raw materials and preparations, medicine, modern bio-pharmaceutical and medical device-based digital; Dalian focus on the development of modern bio-pharmaceutical and chemical agents; Benxi City, focused on the development of traditional Chinese medicine industry. Over the years, Chia seed the pharmaceutical industry in Northeast compared with the greater development of their own, but with the advanced regions, and compared to the world development trend of medicine, pharmaceutical industry in the Northeast, there are still significant gaps.
 First, industry concentration is low. Competition in the world pharmaceutical industry has entered a handful of "oligarchs" rule the roost of the era. Occupy the top ten Chinese medicine 25% of the domestic market, pharmaceutical companies showed a large-scale trends. In contrast, the Northeast serious pharmaceutical companies market concentration is low.
Second, the chain out of line, the industrial structure hypoplasia. Northeast Pharmaceutical industry chain mainly in traditional Chinese medicine and antibiotics industries. Complete industrial chain of Chinese medicine should be: Chinese herbal medicine collection, resveratrol planting - the initial processing of Chinese herbal medicine - Chinese Herbal Medicine and Chinese medicine production - packaging and printing machinery industry and the industry to provide the necessary equipment and accessories. Currently a small number of enterprises in the cultivation of Chinese herbal medicines in accordance with GAP (pharmaceutical plant management practices) requirements to start, but the overall development is not enough; Chinese Herbal Medicine few companies, low levels of technology and equipment; pharmaceutical machinery enterprises only one or two high Precision testing equipment for medical use and purification equipment, mainly rely on imports; drugs are basically within the packaging material procurement from Zhejiang and Jiangsu province.
Third, cluster innovation capability is weak, inadequate investment in research and development, medical innovation system has not been formed. Northeast low degree of specialization in most pharmaceutical companies, bio-medicine and basic chemicals remain in the generic level, the lack of new products with independent intellectual property rights, similar species, repetitive phenomenon seriously. On the one hand, a long time, the real conditions of R & D of new drugs with few pharmaceutical companies in drug discovery, plant extracts research institutions and universities paid little attention to market information, lack of cooperation with enterprises; the other hand, business investment spending in the hardware construction of the main on R & D generally inadequate investment.
Fourth, the low degree of inter-firm cooperation, specialization and cooperation mechanism has been established. Most companies within the industry clusters scattered independent, "small" state to a low degree of organization among enterprises, between enterprises and research institutes lack of cooperation, production efficiency is low, there is no specialization and cooperation to establish joint production network. Large enterprises and SMEs to promote the sound development of the center of the interactive satellite factory system is not enough promotion. Source:http://www.cospcn.com